<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086736</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000353198</org_study_id>
    <secondary_id>UAB-9921</secondary_id>
    <secondary_id>UAB-F990728039</secondary_id>
    <nct_id>NCT00086736</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy</brief_title>
  <official_title>A Randomized, Placebo-Controlled Phase IIb Clinical Trial of 2-Difluoromethylornithine (DFMO) Versus Bicalutamide (CASODEX) Alone and in Combination in Patients With Prostate Cancer in the Period Prior to Radical Prostatectomy or Brachytherapy: Modulation of Tissue and Molecular Biomarkers in Human Prostate Tissue Serum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as eflornithine, work in different ways to stop
      tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of
      prostate cancer cells. Drugs used in hormone therapy, such as bicalutamide, may fight
      prostate cancer by stopping the adrenal glands from producing androgens. Combining
      eflornithine with bicalutamide may kill more tumor cells.

      PURPOSE: Randomized phase II trial to compare the effectiveness of neoadjuvant eflornithine
      and bicalutamide with that of eflornithine alone, bicalutamide alone, and no neoadjuvant
      therapy in treating patients who are undergoing brachytherapy or radical prostatectomy for
      localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare levels of polyamine spermine, polyamine putrescine, and spermidine in patients
           with localized prostate cancer undergoing brachytherapy or radical prostatectomy and
           treated with neoadjuvant eflornithine and bicalutamide vs eflornithine alone vs
           bicalutamide alone vs no neoadjuvant therapy.

        -  Compare the expression of surrogate biomarkers (i.e., serum prostate-specific antigen,
           tissue levels of proliferating cell nuclear antigen, Ki67, and TGF-alpha, apoptosis
           assays [ICH-PARP and TUNEL], and cytomorphometric indices) in patients treated with
           these regimens.

        -  Compare the toxicity of these regimens in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      stratified according to Gleason score (&lt; 7 vs ≥ 7). Patients are randomized to 1 of 4
      treatment arms.

        -  Arm I: Patients receive oral eflornithine and oral bicalutamide once daily.

        -  Arm II: Patients receive oral eflornithine and oral bicalutamide placebo once daily.

        -  Arm III: Patients receive oral eflornithine placebo and oral bicalutamide once daily.

        -  Arm IV: Patients receive oral eflornithine placebo and oral bicalutamide placebo once
           daily.

      In all arms, treatment continues for 28 days in the absence of unacceptable toxicity.
      Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on
      day 29.

      Patients are followed at 4 weeks.

      PROJECTED ACCRUAL: A total of 44 patients (11 per treatment arm) will be accrued for this
      study within 11 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in levels of Polyamine spermine, polyamine putrescine, and spermidine between subjects in each of the 4 groups</measure>
    <time_frame>4 weeks after surgical intervention</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eflornithine</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral eflornithine placebo</intervention_name>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral bicalutamide placebo</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate cancer

               -  Localized disease

          -  Paraffin blocks from diagnostic biopsies available

          -  Planning to undergo brachytherapy or prostatectomy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-3

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Hemoglobin ≥ 10.0 g/dL

          -  WBC ≥ 3,500/mm^3

          -  Platelet count ≥ 125,000/mm^3

        Hepatic

          -  Bilirubin ≤ 2.0 mg/dL

          -  SGOT and SGPT ≤ 2 times normal

          -  No history of liver disease (e.g., hepatitis, cirrhosis, or jaundice)

        Renal

          -  Creatinine ≤ 2.0 mg/dL

        Cardiovascular

          -  No symptomatic coronary artery disease

          -  No uncontrolled hypertension

          -  No acute myocardial infarction within the past year

        Other

          -  Fertile patients must use effective contraception

          -  No more than 10 decibels baseline hearing loss at any frequency by full bilateral
             audiometry within the past month

          -  No hypersensitivity to eflornithine or bicalutamide

          -  No other prior or active malignancy except nonmelanoma skin cancer or other cancer
             curatively treated at least 5 years ago with no evidence of recurrent or residual
             disease

          -  No concurrent acute or chronic medical or psychiatric condition that would preclude
             study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  More than 1 year since prior antiandrogen, luteinizing hormone-releasing hormone
             (LHRH) agonist, bicalutamide, finasteride, or diethylstilbestrol

          -  No other concurrent antiandrogen, LHRH agonist, finasteride, or diethylstilbestrol

        Radiotherapy

          -  See Disease Characteristics

          -  No other concurrent radiotherapy

        Surgery

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald A. Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>November 17, 2013</last_update_submitted>
  <last_update_submitted_qc>November 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

